Profile data is unavailable for this security.
About the company
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
- Revenue in USD (TTM)60.00m
- Net income in USD-78.96m
- Incorporated2006
- Employees112.00
- LocationProtagonist Therapeutics Inc7707 Gateway Blvd Ste 140NEWARK 94560-1160United StatesUSA
- Phone+1 (510) 474-0170
- Fax+1 (302) 636-5454
- Websitehttps://www.protagonist-inc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Akero Therapeutics Inc | 0.00 | -151.76m | 1.35bn | 55.00 | -- | 2.05 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
4D Molecular Therapeutics Inc | 20.72m | -100.84m | 1.35bn | 147.00 | -- | 3.69 | -- | 65.12 | -2.58 | -2.58 | 0.5438 | 7.15 | 0.0689 | -- | -- | 140,972.80 | -33.52 | -32.67 | -35.57 | -34.90 | -- | -- | -486.59 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.37bn | 297.00 | 227.46 | 3.18 | 126.58 | 4.56 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
ANI Pharmaceuticals Inc | 486.82m | 15.48m | 1.41bn | 642.00 | 81.75 | 3.18 | 18.30 | 2.89 | 0.821 | 0.821 | 26.17 | 22.35 | 0.5849 | 1.68 | 2.97 | 758,280.40 | 2.26 | -2.83 | 2.65 | -3.35 | 62.71 | 60.18 | 3.86 | -6.15 | 2.81 | 1.79 | 0.3843 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
Arcus Biosciences Inc | 117.00m | -307.00m | 1.41bn | 577.00 | -- | 2.53 | -- | 12.05 | -4.15 | -4.15 | 1.58 | 6.12 | 0.0959 | -- | 2.89 | 202,773.00 | -25.16 | -15.85 | -29.76 | -18.25 | -- | -- | -262.39 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Morphic Holding Inc | 0.00 | -161.25m | 1.44bn | 124.00 | -- | 2.17 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
Xencor Inc | 168.34m | -126.09m | 1.46bn | 280.00 | -- | 2.16 | -- | 8.65 | -2.10 | -2.10 | 2.79 | 10.96 | 0.1872 | -- | 8.36 | 601,207.10 | -14.04 | -3.70 | -15.30 | -4.12 | -- | -- | -75.00 | -15.92 | -- | -- | 0.0304 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Neumora Therapeutics Inc | 0.00 | -235.93m | 1.47bn | 124.00 | -- | 3.12 | -- | -- | -2.33 | -2.33 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Protagonist Therapeutics Inc | 60.00m | -78.96m | 1.49bn | 112.00 | -- | 4.38 | -- | 24.81 | -1.47 | -1.47 | 1.06 | 5.83 | 0.1981 | -- | 11.56 | 535,714.30 | -26.06 | -35.90 | -28.53 | -41.36 | -- | -- | -131.59 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
Novocure Ltd | 509.34m | -207.04m | 1.53bn | 1.45k | -- | 4.19 | -- | 3.00 | -1.95 | -1.95 | 4.79 | 3.39 | 0.4358 | 3.80 | 6.91 | 350,542.30 | -17.71 | -7.74 | -20.71 | -8.95 | 74.81 | 77.22 | -40.65 | -14.69 | 5.56 | -- | 0.6108 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
Dynavax Technologies Corp | 232.28m | -6.39m | 1.53bn | 408.00 | -- | 2.44 | -- | 6.60 | -0.0733 | -0.0733 | 1.65 | 4.80 | 0.2343 | 0.89 | 2.50 | 569,323.50 | -0.6444 | 4.16 | -0.7216 | 5.71 | 78.40 | 64.83 | -2.75 | 9.19 | 12.96 | -- | 0.2636 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
Day One Biopharmaceuticals Inc | 0.00 | -188.92m | 1.54bn | 155.00 | -- | 4.42 | -- | -- | -2.37 | -2.37 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.11 | -- | -55.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
ADMA Biologics Inc | 258.22m | -28.24m | 1.56bn | 624.00 | -- | 11.27 | -- | 6.05 | -0.1263 | -0.1263 | 1.14 | 0.5981 | 0.7621 | 1.01 | 12.03 | 413,806.10 | -8.33 | -24.80 | -9.60 | -28.00 | 34.44 | 17.02 | -10.94 | -51.31 | 1.69 | 0.924 | 0.4913 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
Kura Oncology Inc | 0.00 | -152.63m | 1.57bn | 142.00 | -- | 3.85 | -- | -- | -2.08 | -2.08 | 0.00 | 5.34 | 0.00 | -- | -- | 0.00 | -33.72 | -26.04 | -36.09 | -27.45 | -- | -- | -- | -- | -- | -- | 0.023 | -- | -- | -- | -12.36 | -- | -- | -- |
Ardelyx Inc | 124.46m | -66.07m | 1.58bn | 267.00 | -- | 9.46 | -- | 12.69 | -0.3038 | -0.3038 | 0.5643 | 0.7176 | 0.5104 | 2.26 | 8.36 | 466,127.30 | -27.10 | -46.14 | -35.55 | -57.32 | 85.70 | 88.15 | -53.08 | -240.87 | 4.64 | -12.70 | 0.23 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Taro Pharmaceutical Industries Ltd | 610.83m | 45.70m | 1.60bn | 1.55k | 34.96 | 0.8981 | 20.13 | 2.62 | 1.22 | 1.22 | 16.25 | 47.33 | 0.2854 | 1.45 | 2.76 | 393,068.20 | 2.14 | 1.85 | 2.59 | 2.21 | 48.02 | 56.82 | 7.48 | 6.99 | 3.03 | -- | 0.00 | 0.00 | 2.07 | -2.85 | -56.33 | -34.53 | -7.64 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Dec 2023 | 5.74m | 9.86% |
Farallon Capital Management LLCas of 31 Dec 2023 | 5.73m | 9.84% |
RTW Investments LPas of 31 Dec 2023 | 5.32m | 9.12% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 4.20m | 7.21% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 3.03m | 5.20% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.73m | 4.69% |
Point72 Asset Management LPas of 31 Dec 2023 | 2.61m | 4.49% |
Kynam Capital Management LPas of 31 Dec 2023 | 2.00m | 3.44% |
Adage Capital Management LPas of 31 Dec 2023 | 1.29m | 2.22% |
Jefferies Investment Advisers LLCas of 31 Dec 2023 | 1.27m | 2.18% |